TIDMSNG
RNS Number : 1397I
Synairgen plc
01 December 2022
Synairgen plc
('Synairgen' or the 'Company')
Board Changes
Southampton, UK - 1 December 2022: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, today announces the appointment of Amanda
Radford FCA to the Board as an independent Non-Executive Director
and Chair of the Audit Committee.
Amanda is an internationally experienced finance leader with
substantial listed company expertise and is currently the Group
Financial Controller of BSI Group, the global B2B company which
employs around 5,500 people and generates revenues of c. GBP600M.
Over the course of her career, Amanda has held senior finance roles
in a number of public companies and has significant experience in
external reporting, financial controls, forecasting and business
planning as well as M&A and fundraising. She has previously
held senior positions at companies including Convatec Group plc,
Post Office Ltd, Pets at Home Vet Group and TalkTalk Telecom
Group.
Starting her career as a qualified chartered accountant, Amanda
trained at Deloitte prior to which she received a BSc in
Biochemistry with Molecular & Cell Biology from Birmingham
University.
Synairgen, furthermore, announces that, after 12 years of
service, Iain Buchanan has retired from the Board and as Chair of
the Remuneration and Nomination Committee. Felicity ('Flic') Gabbay
succeeds Iain as Chair of the Remuneration and Nomination
Committee.
Simon Shaw, Chair of Synairgen, said: "On behalf of the Board,
and personally, I would like to thank Iain for his 12 years of
unstinting service and support to the Board and the Committees on
which he served.
"I would also like to welcome Amanda, whose wealth of experience
will be invaluable to the Synairgen Board as we continue to focus
on the clinical development of SNG001."
Relevant disclosures
The following disclosures are required under Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Mrs Amanda Dawn Radford, aged 52, holds no current
directorships, but has held the following directorships and/or
partnerships in the past five years:
Past directorships:
-- ConvaTec Finance Holdings Limited
-- ConvaTec International U.K. Limited
-- ConvaTec Holdings U.K. Limited
-- British Eventing Limited
Amanda does not have any beneficial interest in the ordinary
shares of the Company.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Alice Lane, Sunila de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of severe viral lung infections, including COVID-19, as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been
granted Fast Track status from the US Food and Drug Administration
(FDA). Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAMZMFMVGFGZZM
(END) Dow Jones Newswires
December 01, 2022 02:00 ET (07:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
